Erratum to: Aflibercept, a New Way to Target Angiogenesis in the Second Line Treatment of Metastatic Colorectal Cancer (mCRC) (Targ Oncol, (2016), 11, (489–500), 10.1007/s11523-016-0447-4);Aflibercept, a New Way to Target Angiogenesis in the Second Line Treatment of Metastatic Colorectal Cancer (mCRC)

Targeted Oncology

Volumn 11, Issue 4, 2016, Pages 489-500

  Scartozzi, Mario ^a   Vincent, Loic ^b   Chiron, Marielle ^b   Cascinu, Stefano ^c  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b SANOFI   (France)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; PLACEBO; PLACENTAL GROWTH FACTOR; RAMUCIRUMAB; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN RECEPTOR; HYBRID PROTEIN;

ABDOMINAL PAIN; AGE; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BINDING AFFINITY; CANCER PROGNOSIS; CONTINUOUS INFUSION; DIARRHEA; DIGESTIVE SYSTEM FISTULA; DIGESTIVE SYSTEM PERFORATION; DRUG SAFETY; DRUG TARGETING; DRUG USE; DRUG WITHDRAWAL; GENE MUTATION; HUMAN; HYPERTENSION; INFECTION; MEDICAL DECISION MAKING; METASTATIC COLORECTAL CANCER; MOUTH ULCER; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHUMAN; ONCOGENE RAS; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEINURIA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR BINDING; STOMATITIS; TREATMENT OUTCOME; TUMOR ESCAPE; VEIN EMBOLISM; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM; VOMITING; COLORECTAL NEOPLASMS; METASTASIS; MOLECULARLY TARGETED THERAPY; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; PROCEDURES;

COLORECTAL NEOPLASMS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS;

EID: 84978082136     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-016-0473-2     Document Type: Erratum

References (45)

1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49:1374–403.
2. I NUMERI DEL CANCRO IN ITALIA 2014. AIOM-AIRTUM; 2014.
3. Van Cutsem E, Cervantes A, Nordlinger B, et al. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Supplement 3):iii1–9.
4. Linee guida AIOM. TUMORI DEL COLON RETTO. Edizione; 2014.
5. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Colon Cancer, version 2.2016.
6. Giordano G, Febbraro A, Venditti M et al. Targeting angiogenesis and tumor microenvironment in metastatic colorectal cancer: role of aflibercept. Gastroenterology Research and Practice 2014, Article ID 526178, 13 pages.
7. Verheul HM, Voest EE, Schlingemann RO. Are tumours angiogenesis-dependent? J Pathol. 2004;202(1):5–13.
8. Zetter BR. Angiogenesis and tumor metastasis. Annu Rev Med. 1998;49:407–24.
9. Ferrarotto R, Hoff PM. Antiangiogenic drugs for colorectal cancer: exploring new possibilities. Clin Colorectal Cancer. 2013;12:1–7.
10. Ciombor KK, Berlin J, Chan E. Aflibercept. Clin Cancer Res. 2013;19(8):1920–5.
11. Rodriguez M. Ziv-Aflibercept use in metastatic colorectal cancer. J Adv Pract Oncol. 2013;4(5):348–52.
12. Yang X, Zhang Y, Yang Y, et al. Vascular endothelial growth factor-dependent spatiotemporal dual roles of placental growth factor in modulation of angiogenesis and tumor growth. Proc Natl Acad Sci U S A. 2013;110(34):13932–7.
13. Bottsford-Miller JN, Coleman RL, Sood AK. Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies. J Clin Oncol. 2012;30(32):4026–34.
14. Kopetz S, Hoff PM, Morris JS. er al. Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol. 2010;28(3):453–9.
15. Loupakis F, Cremolini C, Fioravanti A, et al. Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer. Br J Cancer. 2011;104(8):1262–9.
16. Ebos JM, Lee CR, Bogdanovic E, et al. Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth. Cancer Res. 2008;68(2):521–9.
17. Giampieri R, Scartozzi M, Del Prete M, et al. The “angiogenetic ladder”, step-wise angiogenesis inhibition in metastatic colorectal cancer. Cancer Treat Rev. 2014;40(8):934–41.
18. Patel A, Sun W. Ziv-aflibercept in metastatic colorectal cancer. Biol: Targets Ther. 2014;8:13–25.
19. Dietvorst MHP, Eskens FALM. Current and novel treatment options for metastatic colorectal cancer: emphasis on aflibercept. Biol Ther. 2013;3:25–33.
20. Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012;15:171–85.
21. Tang PA, Moore MJ. Aflibercept in the treatment of patients with metastatic colorectal cancer: latest findings and interpretations. Ther Adv Gastroenterol. 2013;6(6):459–73.
22. Chiron M, Bagley RG, Pollard J, et al. Differential antitumor activity of aflibercept and bevacizumab in patient-derived xenograft models of colorectal cancer. Mol Cancer Ther. 2014;13(6):1636–44.
23. Chiron M, Bagley RG, Pollard J et al. Switching to aflibercept treatment resulted in greater tumor responses than continuous bevacizumab treatment in patient-derived xenograft models of colorectal cancer. In: Proceedings of the 2013 AACR-NCI-EORTC International Conference on Molecular Targets. Mol Cancer Ther. 2013;12(11 Suppl.):Abstract B2.
24. Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol. 2012;30(28):3499–506.
25. Bennouna J, Sastre J, Arnold D, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol. 2013;14(1):29–37.
26. Tabernero J, Yoshino T, Cohn AL, et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol. 2015;16(5):499–508.
27. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;25(12):1539–44.
28. Ruff P, Ferry DR, Lakom R, et al. Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy. Eur J Cancer. 2015;51:18–26.
29. Ruff P, Ferry DR, Papamichael D et al. Observed Benefit of Aflibercept in mCRC Patients ≥ 65 Years: Results of a Prespecified Age-Based Analysis of the VELOUR Study. Ann Oncol. 2013;24(4 Suppl.):iv11–iv24 (O-0017).
30. Tabernero J, Van Cutsem E, Lakomý R, et al. Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial. Eur J Cancer. 2014;50(2):320–31.
31. Hoff PM. The consistency of effect of ziv-aflibercept (Z) in the bevacizumab (B) pre-treated subgroup of patients (pts) in the velour trial stratified by first-line progression ≥ 9 months (mos) versus < 9 mos. J Clin Oncol. 2014;32:5s(Suppl; Abstract 3639).
32. Mitchell E, Van Hazel G, Cunningham D et al. Evaluation of the Effect of Aflibercept (Z) on OS by Timing of 1st Line Disease Progression: A Post-Hoc Analysis of the VELOUR Trial. Ann Oncol. 2014;25(2 Suppl.):ii84 (P-0226).
33. Van Cutsem E, Joulain F, Hoff PM et al. Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy. Target Oncol. 2016;11(3):383–400.
34. Tabernero J, Macarulla T, Humblet Y et al. Aflibercept/FOLFIRI vs. Placebo/FOLFIRI in Metastatic Colorectal Cancer: A Post-Hoc Analysis of Median Overall Survival in VELOUR From the Retrospectively Assessed Time of Starting First-Line Treatment. Ann Oncol. 2014;25(2 Suppl.):ii14–ii104 (P-0288).
35. Chau I, Joulain F, Iqbal SU, et al. A VELOUR post hoc subset analysis: prognostic groups and treatment outcomes in patients with metastatic colorectal cancer treated with aflibercept and FOLFIRI. BMC Cancer. 2014;14:605.
36. Folprecht G, Pericay C, Saunders MP et al. Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first line treatment of patients with metastatic colorectal cancer – the AFFIRM study. Ann Oncol. 2016;27(7):1273–9.
37. Sims T, Gao B, Phillips R, Lowy I. Potential predictive and prognostic biomarkers identified in baseline plasma samples from the VELOUR trial. J Clin Oncol. 2015; 33 (suppl 3; abstr 638).
38. Lambrechts D, Thienpont B, Thuillier, et al. Evaluation of efficacy and safety markers in a phase II study of metastatic colorectal cancer treated with aflibercept in the first-line setting. Br J Cancer. 2015;113(7):1027–34.
39. Frassineti L, Di Bartolomeo M, Heinemann V et al. Aflibercept+FOLFIRI for treatment of metastatic colorectal cancer after oxaliplatin failure:4th Interim Safety Data From the Global Aflibercept Safety and Quality-of-Life Program (ASQoP/AFEQT Studies). Ann Oncol. 2014;25(4 Suppl.):iv167–iv209 (528P).
40. Iaffaioli VR, Pietrantonio F, Pastorino A et al. Aflibercept (afl) plus FOLFIRI for the 2nd-line treatment of patients (pts) with metastatic colorectal cancer (mCRC): 4th interim safety data from the Italian cohort of the Aflibercept Safety and Quality-of-Life Program (ASQoP). AIOM 2014, Poster G14.
41. Taieb J, Bordonaro R, Bencardino K et al. Quality of Life (QoL) on the Aflibercept/FOLFIRI Regimen: 4th Interim Analysis of the Global Aflibercept Safety and Health-Related QoL Program. Ann Oncol. 2014;25(4 Suppl.):iv167–iv209 (529P).
42. Giampieri R, Caporale M, Pietrantonio F, et al. Second-line angiogenesis inhibition in metastatic colorectal cancer patients: Straightforward or overcrowded? Crit Rev Oncol Hematol. 2016;100:99–106.
43. Cremolini C, Schirripa M, Antoniotti C, et al. First-line chemotherapy for mCRC—a review and evidence-based algorithm. Nat Rev Clin Oncol. 2015;12(10):607–19. doi:10.1038/nrclinonc.2015.129.
44. Van Cutsem E, Cervantes A, Nordlinger B, Arnold D, ESMO Guidelines Working Group. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(3 Suppl.):iii1–9.
45. Echave M, Oyagüez I, Lamas MJ, et al. Aflibercept in combination with Folfiri in patients with metastatic colorectal cancer: cost-effectiveness based on velour best efficacy subgroup post-hoc analysis. Value Health. 2015;18(7):A454.